|
|
 Previous Article | Table of Contents | Next Article 
Implications of Potential Cure in Acute Myelogenous Leukemia: Development of Subsequent Cancer and Return to Work
Marcos de Lima,
Sara S. Strom,
Michael Keating,
Hagop Kantarjian,
Sherry Pierce,
Susan O'Brien,
Emil Freireich, and
Elihu Estey
From the Departments of Hematology and Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
Chemotherapy produces extended remissions, and potential cures, in a small minority of patients with acute myeloid leukemia (AML). We explored whether potentially cured patients were at increased risk of subsequent invasive cancer and were able to return to work. Potentially cured patients were defined as those in first or second complete remission (CR) for at least 3 years based on hazard rates for recurrence or death in CR, which declined sharply after this time. Patients who received allogeneic marrow transplant were excluded. We used questionnaires, phone contact, and chart review to obtain information about subsequent cancer and work status. The number of patients who developed invasive cancer was compared with the number expected based on age, gender, and years of follow-up using the Connecticut Tumor Registry. A total of 215 patients met our criteria for potential cure: 203 in first CR and 12 in second CR (of 1,663 treated between 1965 and December, 1992). At a median of 9.2 years from first or second CR, 163 (76%) remain alive in CR. Fifteen patients developed 18 invasive cancers (expected number of patients, 8.8; observed/expected, 1.70; 95% CI, 0.96 to 2.84; P = .06). Patients initially treated between 1973 to 1979, patients above the potentially cured cohort's median age of 40 years, and those who presented with abnormalities of chromosomes 5 and/or 7 were more likely to develop subsequent cancer, whereas the observed/expected ratio for younger patients was 1.05 (95% CI, 0.13 to 3.80; P = .56). Seventy-four percent of the patients who were working full-time and who were under age 50 at time of treatment for AML have been working full-time in the last 6 months. Only 17 of 56 patients who are currently not working cited physical limitation as the reason. Patients with potentially cured AML are likely to be able to return to work, and at least if younger do not, on average, have an increased risk of invasive cancer.
Blood, Vol. 90 No. 12 (December 15), 1997:
pp. 4719-4724
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J.-H. Park, E.-C. Park, J.-H. Park, S.-G. Kim, and S.-Y. Lee
Job Loss and Re-Employment of Cancer Patients in Korean Employees: A Nationwide Retrospective Cohort Study
J. Clin. Oncol.,
March 10, 2008;
26(8):
1302 - 1309.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Estey, C. Koller, A. M. Tsimberidou, S. O'Brien, M. Beran, J. Cortes, M. Tirado-Gomez, G. Lopez-Berestein, and H. Kantarjian
Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid
Blood,
February 1, 2005;
105(3):
1366 - 1367.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. de Lima, A. Anagnostopoulos, M. Munsell, M. Shahjahan, N. Ueno, C. Ippoliti, B. S. Andersson, J. Gajewski, D. Couriel, J. Cortes, et al.
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation
Blood,
August 1, 2004;
104(3):
865 - 872.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Cheson, J. M. Bennett, K. J. Kopecky, T. Buchner, C. L. Willman, E. H. Estey, C. A. Schiffer, H. Doehner, M. S. Tallman, T. A. Lister, et al.
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
J. Clin. Oncol.,
December 15, 2003;
21(24):
4642 - 4649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Wong, S. A. Giralt, T. Martin, D. R. Couriel, A. Anagnostopoulos, C. Hosing, B. S. Andersson, P. Cano, M. Shahjahan, C. Ippoliti, et al.
Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years
Blood,
October 15, 2003;
102(8):
3052 - 3059.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. H. Estey
How I treat older patients with AML
Blood,
September 1, 2000;
96(5):
1670 - 1673.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Socie, J. V. Stone, J. R. Wingard, D. Weisdorf, P. J. Henslee-Downey, C. Bredeson, J.-Y. Cahn, J. R. Passweg, P. A. Rowlings, H. C. Schouten, et al.
Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation
N. Engl. J. Med.,
July 1, 1999;
341(1):
14 - 21.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
